Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Marjolein van Ballegooijen"'
Autor:
Karen Canfell, Shalini L Kulasingam, Inge M.C.M. de Kok, Emily A. Groene, Steffie K. Naber, Kate T. Simms, James Killen, Marjolein van Ballegooijen, Emily A. Burger, Jane J. Kim, Stephen Sy
Publikováno v:
Medical Decision Making, 40(4):0272989x20924007, 474-482. SAGE Publishing
Medical Decision Making
Medical Decision Making
Background. To interpret cervical cancer screening model results, we need to understand the influence of model structure and assumptions on cancer incidence and mortality predictions. Cervical cancer cases and deaths following screening can be attrib
Autor:
Megan Smith, Jane J. Kim, Shalini L Kulasingam, Emily A. Burger, James Killen, Marjolein van Ballegooijen, Catherine Regan, Kate T. Simms, Inge M.C.M. de Kok, Susan Yuill, Karen Canfell
Publikováno v:
Gynecol Oncol
Gynecologic Oncology, 158(3), 710-718. Academic Press
Gynecologic Oncology, 158(3), 710-718. Academic Press
Background SEER-reported cervical cancer incidence rates reflect the total female population including women no longer at risk due to hysterectomy. Hysterectomy rates have been declining in the United States as alternative treatments have become avai
Autor:
Megan Smith, Jane J. Kim, Shalini L Kulasingam, Vivek Vaidyanathan, Kate T. Simms, Stephen Sy, Karen M. Kuntz, Karen Canfell, Emily A. Burger, Inge M.C.M. de Kok, James Killen, Fernando Alarid-Escudero, Emily A. Groene, Marjolein van Ballegooijen, Catherine Regan, Suzette M. Matthijsse
Publikováno v:
Journal of the National Cancer Institute, 112(9), 955-963. Oxford University Press
J Natl Cancer Inst
J Natl Cancer Inst
Background The natural history of human papillomavirus (HPV)-induced cervical cancer (CC) is not directly observable, yet the age of HPV acquisition and duration of preclinical disease (dwell time) influences the effectiveness of alternative preventi
Autor:
Harry J. de Koning, Monique E. van Leerdam, Evelien Dekker, Christian Ramakers, Iris Lansdorp-Vogelaar, Miriam P. van der Meulen, Harriët van Veldhuizen, Anneke J van Vuuren, Marjolein van Ballegooijen, Folkert J. van Kemenade, Marc H M Thelen, Johannes M.G. Bonfrer, Maaike Buskermolen, Maarten Thomeer, Esther Toes-Zoutendijk, Marie-Louise F. van Velthuysen, Manon C.W. Spaander, Ernst J. Kuipers
Publikováno v:
Clinical Chemistry, 65(3), 419-426. American Association for Clinical Chemistry Inc.
Clinical chemistry, 65(3), 419-426. American Association for Clinical Chemistry Inc.
Clinical chemistry, 65(3), 419-426. American Association for Clinical Chemistry Inc.
BACKGROUND Quality assessment is crucial for consistent program performance of colorectal cancer (CRC) screening programs using fecal immunochemical test for hemoglobin (FIT). However, literature on the consistency of FIT performance in laboratory me
Autor:
Marjolein van Ballegooijen, Steffie K. Naber, Emi Naslazi, Jan A. C. Hontelez, Inge M.C.M. de Kok
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Cancer Epidemiology Biomarkers & Prevention, 30(5), 912-919. American Association for Cancer Research Inc.
Cancer Epidemiology Biomarkers & Prevention, 30(5), 912-919. American Association for Cancer Research Inc.
Background: With increased uptake of vaccination against human papillomavirus (HPV), protection against cervical cancer will also increase for unvaccinated women, due to herd immunity. Still, the differential risk between vaccinated and unvaccinated
Autor:
Clare A. Aitken, Steffie K. Naber, Erik E.L. Jansen, Inge M.C.M. de Kok, Marjolein van Ballegooijen, Harry J. de Koning
Publikováno v:
BJOG: An International Journal of Obstetrics & Gynaecology
BJOG: An International Journal of Obstetrics and Gynaecology, 128(3), 573-582. Wiley-Blackwell Publishing Ltd
BJOG: An International Journal of Obstetrics and Gynaecology, 128(3), 573-582. Wiley-Blackwell Publishing Ltd
Objective: We aim to compare the cost-effectiveness of the old cytology programme with the new high-risk human papillomavirus (hrHPV) screening programme, using performance indicators from the new Dutch hrHPV screening programme. Design: Model-based
Autor:
Erik E.L. Jansen, Nadine Zielonke, Andrea Gini, Ahti Anttila, Nereo Segnan, Zoltán Vokó, Urška Ivanuš, Martin McKee, Harry J. de Koning, Inge M.C.M. de Kok, Piret Veerus, Sirpa Heinävaara, Tytti Sarkeala, Marcell Csanádi, Janos Pitter, György Széles, Silvia Minozzi, Carlo Senore, Marjolein van Ballegooijen, Inge Driesprong - de Kok, Eveline Heijnsdijk, Erik Jansen, Harry de Koning, Iris Lansdorp – Vogelaar, Nicolien van Ravesteyn, Urska Ivanus, Katja Jarm, Dominika Novak Mlakar, Maja Primic-Žakelj, Jennifer Priaulx
Publikováno v:
European Journal of Cancer, 127, 207-223. Elsevier Ltd.
European Journal of Cancer
European Journal of Cancer
Background Organised cervical cancer (CC) screening programmes are delivered in many different ways across the European Union and its regions. Our aim was to systematically review the impact of these programs on CC mortality. Methods Two independent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f4da5c949db1d9c43540e81836b64cb
https://pure.eur.nl/en/publications/48f2d950-3e90-422c-b315-a866fa40662b
https://pure.eur.nl/en/publications/48f2d950-3e90-422c-b315-a866fa40662b
Autor:
Christian Ramakers, Marieke A.M. Frasa, Annemieke W.J. Opstal-van Winden, Gerrit A. Meijer, Ernst J. Kuipers, W.M.U. Van Grevenstein, Tj. Wiersma, Iris Lansdorp-Vogelaar, Harry J. de Koning, Geraldine R. Vink, Esther Toes-Zoutendijk, Evelien Dekker, J.A. Otte, Iris D. Nagtegaal, A. van der Beek, J. van Bergeijk, Marie-Louise F. van Velthuysen, L.H.J. Jacobs, E. J. R. de Graaf, Ad A.M. Masclee, Marloes A. G. Elferink, Folkert J. van Kemenade, Manon C.W. Spaander, Arthur I. Kooyker, Marjolein van Ballegooijen, Harriët van Veldhuizen, Monique E. van Leerdam, Jaap Stoker, Maarten Thomeer, Anneke J van Vuuren, Maaike Buskermolen
Publikováno v:
Clinical Gastroenterology and Hepatology, 18(7), 1493-1500. W.B. Saunders
Clinical gastroenterology and hepatology, 18(7), 1493-1500. W.B. Saunders Ltd
Clinical Gastroenterology and Hepatology, 18, 1493-1500
Clinical Gastroenterology and Hepatology, 18(7), 1493-1500. ELSEVIER SCIENCE INC
Clinical Gastroenterology and Hepatology, 18, 7, pp. 1493-1500
Clinical gastroenterology and hepatology, 18(7), 1493-1500. W.B. Saunders Ltd
Clinical Gastroenterology and Hepatology, 18, 1493-1500
Clinical Gastroenterology and Hepatology, 18(7), 1493-1500. ELSEVIER SCIENCE INC
Clinical Gastroenterology and Hepatology, 18, 7, pp. 1493-1500
Contains fulltext : 220797pub.pdf (Publisher’s version ) (Open Access) BACKGROUND & AIMS: We evaluated the incidence of interval cancers between the first and second rounds of colorectal cancer (CRC) screening with the FOB-Gold fecal immunochemical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b017313265cd95870ad87d6340feec58
https://pure.eur.nl/en/publications/04087563-cc46-40d9-8d37-54d5598cb1b9
https://pure.eur.nl/en/publications/04087563-cc46-40d9-8d37-54d5598cb1b9
Autor:
Linda J.W. Bosch, Iris Lansdorp-Vogelaar, Veerle Melotte, Manon van Engeland, S. Lucas Goede, Gerrit A. Meijer, Beatriz Carvalho, Harry J. de Koning, Marjolein van Ballegooijen
Publikováno v:
Clinical Gastroenterology and Hepatology, 16(4), 504-512.e11. W.B. Saunders Ltd
Lansdorp-Vogelaar, I, Goede, S L, Bosch, L J W, Melotte, V, Carvalho, B, van Engeland, M, Meijer, G A, de Koning, H J & van Ballegooijen, M 2018, ' Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening ', Clinical Gastroenterology and Hepatology, vol. 16, no. 4, pp. 504-512.e11 . https://doi.org/10.1016/j.cgh.2017.07.011
Clinical gastroenterology and hepatology, 16(4), 504-12. Elsevier Science
Clinical Gastroenterology and Hepatology, 16(4), 504-+. W.B. Saunders
Lansdorp-Vogelaar, I, Goede, S L, Bosch, L J W, Melotte, V, Carvalho, B, van Engeland, M, Meijer, G A, de Koning, H J & van Ballegooijen, M 2018, ' Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening ', Clinical Gastroenterology and Hepatology, vol. 16, no. 4, pp. 504-512.e11 . https://doi.org/10.1016/j.cgh.2017.07.011
Clinical gastroenterology and hepatology, 16(4), 504-12. Elsevier Science
Clinical Gastroenterology and Hepatology, 16(4), 504-+. W.B. Saunders
BACKGROUND & AIMS: Biomarker assays could increase the accuracy of noninvasive detection of colorectal cancer (CRC); fecal immunochemical tests (FITs) are estimated to miss 27%-47% of CRCs and 70%-80% of advanced adenomas per round of screening. We i
Autor:
Sylvia K. Plevritis, Mucahit Cevik, Natasha K. Stout, Jeanne S. Mandelblatt, Marjolein van Ballegooijen, Hui Huang, Diego F. Munoz, Harry J. de Koning, Yisheng Li, Sandra J. Lee, Nicolien T. van Ravesteyn, Jeroen J. van den Broek, Clyde B. Schechter
Publikováno v:
Medical Decision Making, 38, 112S-125S. SAGE Publishing
Background. Collaborative modeling has been used to estimate the impact of potential cancer screening strategies worldwide. A necessary step in the interpretation of collaborative cancer screening model results is to understand how model structure an